mRNA-2752

N/A

Report date: 2024/06/28 13:29:49

Base Information

Drug NamemRNA-2752
Drug Alias NameLipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γmRNA-2752
ClassificationCell and gene therapy > Gene therapy > mRNA
Mechanisms of ActionProtein biosynthesis stimulantsTumor necrosis factor ligand superfamily member 4 agonistsInterleukin-36 gamma stimulants +[4] 
TargetsTumor necrosis factor ligand superfamily member 4Interleukin-36 gammaInterleukin-23
Therapy Area/IndicationsSolid tumoursLymphomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaIsrael
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesModerna IncAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesModerna IncAstrazeneca Plc
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A